Showing 3611-3620 of 4063 results for "".
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- Lensar Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrellhttps://modernod.com/news/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-ofarrell/2478817/Lensar announced the expansion of its board of directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. In addition to serving on the company’s Board of Directors, Ms. Weisner will
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- Johnson & Johnson Vision Names Peter Menziuso New Worldwide President for Vision Carehttps://modernod.com/news/johnson-johnson-vision-announces-peter-menziuso-as-the-new-worldwide-president-for-vision-care/2478812/Johnson & Johnson Vision announced that Peter Menziuso will assume the role of Worldwide President, Vision Care, for Johnson & Johnson Vision immediately. Mr. Menziuso replaces Swami Raote, who retired at the end of 2020, after a 29-year tenure with Johnson & Johnson. Mr. Menzi
- DORC Announces Health Canada Approval of Tissueblue for Staining of the ILM During Vitreoretinal Surgeryhttps://modernod.com/news/dorc-announces-health-canada-approval-of-tissueblue-for-staining-of-the-ilm-during-vitreoretinal-surgery/2478799/DORC has announced that it has received notification from Health Canada that the application for Tissueblue (Brilliant Blue G Ophthalmic Solution 0.025%) has been approved and will be available later in 2021 via Innovamed, DORC’s local distributor partner. Tissueblue is the first dye approved by
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- Oxurion NV Appoints Prof Alan Stitt as Chief Scientific Officerhttps://modernod.com/news/oxurion-nv-appoints-prof-alan-stitt-as-chief-scientific-officer/2478775/Oxurion has announced the appointment of Professor Alan Stitt, PhD, as the company’s Chief Scientific Officer (CSO), effective January 19, 2021. This appointment follows the retirement of current CSO Jean Feyen, PhD, who has served in this position since joining the company in 2013. Dr. Feyen wil
- More Adults with Vision Loss Seeking Help Staying Connected During Pandemichttps://modernod.com/news/more-adults-with-vision-loss-seeking-help-staying-connected-during-pandemic/2478772/Since the onset of COVID-19 those with visual impairments have faced disproportionate vulnerabilities from living in extended isolation. Newly released data has shown that clinical depression within the visually impaired community is being reported at nearly three times the level than the general
- Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participantshttps://modernod.com/news/early-study-shows-jjs-one-dose-covid-19-vaccine-triggered-antibodies-in-all-participants/2478759/Detailed phase 1/2a study findings published in the NEJM on Wednesday showed that all volunteers given Johnson & Johnson’s single-dose coronavirus vaccine Ad26.COV2.S had detectable neutralizing antibodies by day 57. In September, the company reported a preview of the interim results in
- GenSight Biologics Announces Publication of Results from Lumevoq RESCUE Phase 3 Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-rescue-phase-3-trial/2478755/GenSight Biologics announced that Ophthalmology has published results from the RESCUE pivotal phase 3 clinical trial of Lumevoq gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper, published in the January issue under the title, “Efficacy and safety